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INTRODUCTION AND OBJECTIVES: RASAL2 is a member of RAS GTPase-activating proteins, but its roles in different cancer types remain controversial. Previously, we have demonstrated RASAL2 could act as a tumor suppressor to modulate epithelial-mesenchymal transition (EMT) and stemness, which were critical for bladder cancer (BCa) recurrence and metastasis. However, its potential roles in tumor angiogenesis of BCa are largely unknown.
METHODS: In vitro, Two BCa cell lines (253J-BV and 5637 cells) and their sublines with different RASAL2 expression levels were employed to investigate the recruitment and tube formation of human umbilical vein endothelial cell (HUVEC) by HUVEC migration assay and tube formation assay. The expression of VEGFA and its upstream signaling transduction were explored by ELISA assay and western blot analysis. In vivo, subcutaneous xenografts in nude mice were used to detect tumorigenicity. Moreover, the expression of RASAL2, VEGFA and CD31 in xenografts and human BCa tissues was detected by immunohistochemical (IHC) staining.
RESULTS: RASAL2 overexpression in 253J-BV cells could inhibit the recruitment and tube formation of HUVECs, meanwhile RASAL2 knockdown (KD) in 5637 cells enhanced the recruitment and tube formation of HUVECs in vitro. Consistently, RASAL2 overexpression in 253J-BV cells could suppress tumorigenecity in vivo. Mechanistically, RASAL2 downregulation could enhance the phosphorylation of AKT and then subsequently upregulate the expression of ETS1 and VEGFA, because PI3K inhibitor LY294002 or ETS1 siRNA could rescue the expression of VEGFA in RASAL2 KD cells while AKT activator SC-79 could also rescue the expression of VEGFA in RASAL2 overexpressed cells. Furthermore, RASAL2 was inversely correlated with VEGFA and CD31 in tissues from subcutaneous xenografts and human BCa specimens.
CONCLUSIONS: Besides the regulation of EMT and stemness, RASAL2 could also inhibit tumor angiogenesis via p-AKT/ETS1 signaling, which may play a critical role in BCa development and progression.
Source of Funding: Grants from the National Natural Science Foundation of China (NSFC 81572516 to KW) and International Science and technology cooperation and exchange program in Shaanxi Province (2016KW-021 to KW). INTRODUCTION AND OBJECTIVES: Introduction: Percutaneous nephrolithotomy (PNL) or retrograde intrarenal surgery (RIRS) is recommended for the treatment of 1-2 cm lower pole (LP) renal calculi. However, the optimal treatment option remains controversial, and level 1 evidence comparing the two modalities is still deficient.Objective: A multinational multicenter prospective randomized comparison of supermini percutaneous nephrolithotomy (SMP) and retrograde intrarenal surgery (RIRS) for the treatment of 1 to 2 cm LP renal calculi was done to evaluate the safety and efficacy of these procedures.
METHODS: 153 patients with 1 to 2 cm LP renal calculi who underwent treatment between August 2015 and March 2017 were included in this study at 9 Asian centers and 1 European center. These patients were randomized to SMP and RIRS groups. One-session stone-free rate (SFR) and SFR at 1-month postoperatively were analyzed as the primary outcomes. The secondary outcomes analyses included blood loss, operative duration, postoperative pain scores, auxiliary procedures, complications and hospital stay. The study was registered at http://clinicaltrials.gov /(NCT02519634).
RESULTS: The SFR was significantly higher in the SMP group than in the RIRS group (one-session SFR 94.8% and 75.0%, P ¼0.001; overall SFR at 1-month postoperatively 97.4% and 84.2%, P ¼0.005). The auxiliary rate was lower in the SMP group (p ¼0.001). RIRS was found to be superior in terms of lower haemoglobin drop (P <0.001) and less postoperative pain scores at 6 h, 24 h and 48 h (P ¼ 0.001, P ¼ 0.004 and P ¼ 0.043, respectively).There was no significant difference in the operating time and hospital stay. The overall complication rates were similar in the both groups.
CONCLUSIONS: SMP provides overall significantly higher SFR and lower auxiliary rate compared to RIRS in the treatment of 1-2 cm LP calculi, with no significant differences in surgical time and hospital stay. However RIRS was found to be advantageous regarding the haemoglobin drop rates and postoperative pain scores.
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